APO Research
Talk to an analyst

APO RESEARCH · REPORT

Interleukin Inhibitors for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Interleukin Inhibitors for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025196 pages

Choose your research edition.

Industry ResearchInterleukin Inhibitors for Psoriasis Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Interleukin Inhibitors for Psoriasis Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Interleukin Inhibitors for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Interleukin Inhibitors for Psoriasis Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Interleukin Inhibitors for Psoriasis Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Interleukin Inhibitors for Psoriasis market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Interleukin Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Interleukin Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Interleukin Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Interleukin Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Interleukin Inhibitors for Psoriasis include AbbVie Biotechnology, Almirall, Janssen Biotech, LEO Pharma, Novartis, Ortho Dermatologics, Samsung Bioepis, Sun Pharma and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Interleukin Inhibitors for Psoriasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Interleukin Inhibitors for Psoriasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Interleukin Inhibitors for Psoriasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Interleukin Inhibitors for Psoriasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Interleukin Inhibitors for Psoriasis Segment by Company

AbbVie Biotechnology

Almirall

Janssen Biotech

LEO Pharma

Novartis

Ortho Dermatologics

Samsung Bioepis

Sun Pharma

UCB

Dalian Yawei Pharmaceutical

China Medical System

Eli Lilly

Teva

Kyowa Kirin

Interleukin Inhibitors for Psoriasis Segment by Type

Interleukin-8 Inhibitors

Interleukin-23 Inhibitors

Interleukin-17 Inhibitors

Interleukin-12 Inhibitors

Other

Interleukin Inhibitors for Psoriasis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Interleukin Inhibitors for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin Inhibitors for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Interleukin Inhibitors for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin Inhibitors for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Interleukin Inhibitors for Psoriasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Interleukin Inhibitors for Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Interleukin Inhibitors for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Interleukin Inhibitors for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Interleukin Inhibitors for Psoriasis Industry Trends Table 2. Interleukin Inhibitors for Psoriasis Industry Drivers Table 3. Interleukin Inhibitors for Psoriasis Industry Opportunities and Challenges Table 4. Interleukin Inhibitors for Psoriasis Industry Restraints Table 5. Global Interleukin Inhibitors for Psoriasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Interleukin Inhibitors for Psoriasis Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Manufacturers Table 9. Global Interleukin Inhibitors for Psoriasis Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Interleukin Inhibitors for Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Interleukin Inhibitors for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Interleukin Inhibitors for Psoriasis Manufacturers, Product Type & Application Table 13. Global Interleukin Inhibitors for Psoriasis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Interleukin Inhibitors for Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Interleukin-8 Inhibitors Table 17. Major Manufacturers of Interleukin-23 Inhibitors Table 18. Major Manufacturers of Interleukin-17 Inhibitors Table 19. Major Manufacturers of Interleukin-12 Inhibitors Table 20. Major Manufacturers of Other Table 21. Global Interleukin Inhibitors for Psoriasis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Interleukin Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units) Table 23. Global Interleukin Inhibitors for Psoriasis Sales by Type (2027-2032) & (K Units) Table 24. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2021-2026) Table 25. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2027-2032) Table 26. Global Interleukin Inhibitors for Psoriasis Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Interleukin Inhibitors for Psoriasis Revenue by Type (2021-2026) & (K Units) Table 28. Global Interleukin Inhibitors for Psoriasis Revenue by Type (2027-2032) & (K Units) Table 29. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026) Table 30. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital and Clinic Table 32. Major Manufacturers of Retail Pharmacies Table 33. Major Manufacturers of Other Table 34. Global Interleukin Inhibitors for Psoriasis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Interleukin Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units) Table 36. Global Interleukin Inhibitors for Psoriasis Sales by Application (2027-2032) & (K Units) Table 37. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2021-2026) Table 38. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2027-2032) Table 39. Global Interleukin Inhibitors for Psoriasis Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Interleukin Inhibitors for Psoriasis Revenue by Application (2021-2026) & (K Units) Table 41. Global Interleukin Inhibitors for Psoriasis Revenue by Application (2027-2032) & (K Units) Table 42. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2021-2026) Table 43. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2027-2032) Table 44. Global Interleukin Inhibitors for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Interleukin Inhibitors for Psoriasis Sales by Region (2021-2026) & (K Units) Table 46. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Region (2021-2026) Table 47. Global Interleukin Inhibitors for Psoriasis Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Interleukin Inhibitors for Psoriasis Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Interleukin Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Interleukin Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units) Table 51. North America Interleukin Inhibitors for Psoriasis Sales by Country (2027-2032) & (K Units) Table 52. Europe Interleukin Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Interleukin Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units) Table 54. Europe Interleukin Inhibitors for Psoriasis Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Interleukin Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Interleukin Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Interleukin Inhibitors for Psoriasis Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Sales by Country (2027-2032) & (K Units) Table 61. Global Interleukin Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Interleukin Inhibitors for Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Interleukin Inhibitors for Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Region (2021-2026) Table 65. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Region (2027-2032) Table 66. AbbVie Biotechnology Company Information Table 67. AbbVie Biotechnology Business Overview Table 68. AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Product Portfolio Table 70. AbbVie Biotechnology Recent Development Table 71. Almirall Company Information Table 72. Almirall Business Overview Table 73. Almirall Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Almirall Interleukin Inhibitors for Psoriasis Product Portfolio Table 75. Almirall Recent Development Table 76. Janssen Biotech Company Information Table 77. Janssen Biotech Business Overview Table 78. Janssen Biotech Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Janssen Biotech Interleukin Inhibitors for Psoriasis Product Portfolio Table 80. Janssen Biotech Recent Development Table 81. LEO Pharma Company Information Table 82. LEO Pharma Business Overview Table 83. LEO Pharma Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. LEO Pharma Interleukin Inhibitors for Psoriasis Product Portfolio Table 85. LEO Pharma Recent Development Table 86. Novartis Company Information Table 87. Novartis Business Overview Table 88. Novartis Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Novartis Interleukin Inhibitors for Psoriasis Product Portfolio Table 90. Novartis Recent Development Table 91. Ortho Dermatologics Company Information Table 92. Ortho Dermatologics Business Overview Table 93. Ortho Dermatologics Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Ortho Dermatologics Interleukin Inhibitors for Psoriasis Product Portfolio Table 95. Ortho Dermatologics Recent Development Table 96. Samsung Bioepis Company Information Table 97. Samsung Bioepis Business Overview Table 98. Samsung Bioepis Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Samsung Bioepis Interleukin Inhibitors for Psoriasis Product Portfolio Table 100. Samsung Bioepis Recent Development Table 101. Sun Pharma Company Information Table 102. Sun Pharma Business Overview Table 103. Sun Pharma Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Sun Pharma Interleukin Inhibitors for Psoriasis Product Portfolio Table 105. Sun Pharma Recent Development Table 106. UCB Company Information Table 107. UCB Business Overview Table 108. UCB Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. UCB Interleukin Inhibitors for Psoriasis Product Portfolio Table 110. UCB Recent Development Table 111. Dalian Yawei Pharmaceutical Company Information Table 112. Dalian Yawei Pharmaceutical Business Overview Table 113. Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Product Portfolio Table 115. Dalian Yawei Pharmaceutical Recent Development Table 116. China Medical System Company Information Table 117. China Medical System Business Overview Table 118. China Medical System Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. China Medical System Interleukin Inhibitors for Psoriasis Product Portfolio Table 120. China Medical System Recent Development Table 121. Eli Lilly Company Information Table 122. Eli Lilly Business Overview Table 123. Eli Lilly Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Eli Lilly Interleukin Inhibitors for Psoriasis Product Portfolio Table 125. Eli Lilly Recent Development Table 126. Teva Company Information Table 127. Teva Business Overview Table 128. Teva Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Teva Interleukin Inhibitors for Psoriasis Product Portfolio Table 130. Teva Recent Development Table 131. Kyowa Kirin Company Information Table 132. Kyowa Kirin Business Overview Table 133. Kyowa Kirin Interleukin Inhibitors for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Kyowa Kirin Interleukin Inhibitors for Psoriasis Product Portfolio Table 135. Kyowa Kirin Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Interleukin Inhibitors for Psoriasis Distributors List Table 139. Interleukin Inhibitors for Psoriasis Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Interleukin Inhibitors for Psoriasis Product Image Figure 2. Global Interleukin Inhibitors for Psoriasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Interleukin Inhibitors for Psoriasis Market Size (2021-2032) & (US$ Million) Figure 4. Global Interleukin Inhibitors for Psoriasis Sales (2021-2032) & (K Units) Figure 5. Global Interleukin Inhibitors for Psoriasis Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Interleukin Inhibitors for Psoriasis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Interleukin-8 Inhibitors Image Figure 9. Interleukin-23 Inhibitors Image Figure 10. Interleukin-17 Inhibitors Image Figure 11. Interleukin-12 Inhibitors Image Figure 12. Other Image Figure 13. Global Interleukin Inhibitors for Psoriasis Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Interleukin Inhibitors for Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2021-2032) Figure 16. Global Interleukin Inhibitors for Psoriasis Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Interleukin Inhibitors for Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Type (2021-2032) Figure 19. Hospital and Clinic Image Figure 20. Retail Pharmacies Image Figure 21. Other Image Figure 22. Global Interleukin Inhibitors for Psoriasis Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Interleukin Inhibitors for Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2021-2032) Figure 25. Global Interleukin Inhibitors for Psoriasis Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Interleukin Inhibitors for Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2021-2032) Figure 28. North America Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2021-2032) Figure 30. U.S. Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2021-2032) Figure 35. Germany Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2021-2032) Figure 42. China Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2021-2032) Figure 50. Brazil Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Interleukin Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Interleukin Inhibitors for Psoriasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Interleukin Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 61. North America Interleukin Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Interleukin Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 63. Europe Interleukin Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Interleukin Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Interleukin Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Interleukin Inhibitors for Psoriasis Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Interleukin Inhibitors for Psoriasis Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Interleukin-8 Inhibitors
  • Interleukin-23 Inhibitors
  • Interleukin-17 Inhibitors
  • Interleukin-12 Inhibitors
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • AbbVie Biotechnology
  • Almirall
  • Janssen Biotech
  • LEO Pharma
  • Novartis
  • Ortho Dermatologics
  • Samsung Bioepis
  • Sun Pharma
  • UCB
  • Dalian Yawei Pharmaceutical
  • China Medical System
  • Eli Lilly
  • Teva
  • Kyowa Kirin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Interleukin Inhibitors for Psoriasis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Interleukin Inhibitors for Psoriasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Interleukin Inhibitors for Psoriasis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Interleukin Inhibitors for Psoriasis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Interleukin Inhibitors for Psoriasis Market Dynamics
  1. 2.1 Interleukin Inhibitors for Psoriasis Industry Trends
  2. 2.2 Interleukin Inhibitors for Psoriasis Industry Drivers
  3. 2.3 Interleukin Inhibitors for Psoriasis Industry Opportunities and Challenges
  4. 2.4 Interleukin Inhibitors for Psoriasis Industry Restraints
3 Interleukin Inhibitors for Psoriasis Market by Manufacturers
  1. 3.1 Global Interleukin Inhibitors for Psoriasis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Interleukin Inhibitors for Psoriasis Sales by Manufacturers (2021-2026)
  3. 3.3 Global Interleukin Inhibitors for Psoriasis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Interleukin Inhibitors for Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Interleukin Inhibitors for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Interleukin Inhibitors for Psoriasis Manufacturers, Product Type & Application
  7. 3.7 Global Interleukin Inhibitors for Psoriasis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Interleukin Inhibitors for Psoriasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Interleukin Inhibitors for Psoriasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Interleukin Inhibitors for Psoriasis Tier 1, Tier 2, and Tier 3
4 Interleukin Inhibitors for Psoriasis Market by Type
  1. 4.1 Interleukin Inhibitors for Psoriasis Type Introduction
  2. 4.1.1 Interleukin-8 Inhibitors
  3. 4.1.2 Interleukin-23 Inhibitors
  4. 4.1.3 Interleukin-17 Inhibitors
  5. 4.1.4 Interleukin-12 Inhibitors
  6. 4.1.5 Other
  7. 4.2 Global Interleukin Inhibitors for Psoriasis Sales by Type
  8. 4.2.1 Global Interleukin Inhibitors for Psoriasis Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Interleukin Inhibitors for Psoriasis Sales by Type (2021-2032)
  10. 4.2.3 Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2021-2032)
  11. 4.3 Global Interleukin Inhibitors for Psoriasis Revenue by Type
  12. 4.3.1 Global Interleukin Inhibitors for Psoriasis Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Interleukin Inhibitors for Psoriasis Revenue by Type (2021-2032)
  14. 4.3.3 Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Type (2021-2032)
5 Interleukin Inhibitors for Psoriasis Market by Application
  1. 5.1 Interleukin Inhibitors for Psoriasis Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Interleukin Inhibitors for Psoriasis Sales by Application
  6. 5.2.1 Global Interleukin Inhibitors for Psoriasis Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Interleukin Inhibitors for Psoriasis Sales by Application (2021-2032)
  8. 5.2.3 Global Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2021-2032)
  9. 5.3 Global Interleukin Inhibitors for Psoriasis Revenue by Application
  10. 5.3.1 Global Interleukin Inhibitors for Psoriasis Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Interleukin Inhibitors for Psoriasis Revenue by Application (2021-2032)
  12. 5.3.3 Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2021-2032)
6 Global Interleukin Inhibitors for Psoriasis Sales by Region
  1. 6.1 Global Interleukin Inhibitors for Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Interleukin Inhibitors for Psoriasis Sales by Region (2021-2032)
  3. 6.2.1 Global Interleukin Inhibitors for Psoriasis Sales by Region (2021-2026)
  4. 6.2.2 Global Interleukin Inhibitors for Psoriasis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Interleukin Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Interleukin Inhibitors for Psoriasis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Interleukin Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Interleukin Inhibitors for Psoriasis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Interleukin Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Interleukin Inhibitors for Psoriasis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Interleukin Inhibitors for Psoriasis Revenue by Region
  1. 7.1 Global Interleukin Inhibitors for Psoriasis Revenue by Region
  2. 7.1.1 Global Interleukin Inhibitors for Psoriasis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Interleukin Inhibitors for Psoriasis Revenue by Region (2021-2026)
  4. 7.1.3 Global Interleukin Inhibitors for Psoriasis Revenue by Region (2027-2032)
  5. 7.1.4 Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Interleukin Inhibitors for Psoriasis Revenue (2021-2032)
  8. 7.2.2 North America Interleukin Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Interleukin Inhibitors for Psoriasis Revenue (2021-2032)
  11. 7.3.2 Europe Interleukin Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Interleukin Inhibitors for Psoriasis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Interleukin Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie Biotechnology
  2. 8.1.1 AbbVie Biotechnology Company Information
  3. 8.1.2 AbbVie Biotechnology Business Overview
  4. 8.1.3 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Product Portfolio
  6. 8.1.5 AbbVie Biotechnology Recent Developments
  7. 8.2 Almirall
  8. 8.2.1 Almirall Company Information
  9. 8.2.2 Almirall Business Overview
  10. 8.2.3 Almirall Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Almirall Interleukin Inhibitors for Psoriasis Product Portfolio
  12. 8.2.5 Almirall Recent Developments
  13. 8.3 Janssen Biotech
  14. 8.3.1 Janssen Biotech Company Information
  15. 8.3.2 Janssen Biotech Business Overview
  16. 8.3.3 Janssen Biotech Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Janssen Biotech Interleukin Inhibitors for Psoriasis Product Portfolio
  18. 8.3.5 Janssen Biotech Recent Developments
  19. 8.4 LEO Pharma
  20. 8.4.1 LEO Pharma Company Information
  21. 8.4.2 LEO Pharma Business Overview
  22. 8.4.3 LEO Pharma Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 LEO Pharma Interleukin Inhibitors for Psoriasis Product Portfolio
  24. 8.4.5 LEO Pharma Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Interleukin Inhibitors for Psoriasis Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Ortho Dermatologics
  32. 8.6.1 Ortho Dermatologics Company Information
  33. 8.6.2 Ortho Dermatologics Business Overview
  34. 8.6.3 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Product Portfolio
  36. 8.6.5 Ortho Dermatologics Recent Developments
  37. 8.7 Samsung Bioepis
  38. 8.7.1 Samsung Bioepis Company Information
  39. 8.7.2 Samsung Bioepis Business Overview
  40. 8.7.3 Samsung Bioepis Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Samsung Bioepis Interleukin Inhibitors for Psoriasis Product Portfolio
  42. 8.7.5 Samsung Bioepis Recent Developments
  43. 8.8 Sun Pharma
  44. 8.8.1 Sun Pharma Company Information
  45. 8.8.2 Sun Pharma Business Overview
  46. 8.8.3 Sun Pharma Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharma Interleukin Inhibitors for Psoriasis Product Portfolio
  48. 8.8.5 Sun Pharma Recent Developments
  49. 8.9 UCB
  50. 8.9.1 UCB Company Information
  51. 8.9.2 UCB Business Overview
  52. 8.9.3 UCB Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 UCB Interleukin Inhibitors for Psoriasis Product Portfolio
  54. 8.9.5 UCB Recent Developments
  55. 8.10 Dalian Yawei Pharmaceutical
  56. 8.10.1 Dalian Yawei Pharmaceutical Company Information
  57. 8.10.2 Dalian Yawei Pharmaceutical Business Overview
  58. 8.10.3 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Product Portfolio
  60. 8.10.5 Dalian Yawei Pharmaceutical Recent Developments
  61. 8.11 China Medical System
  62. 8.11.1 China Medical System Company Information
  63. 8.11.2 China Medical System Business Overview
  64. 8.11.3 China Medical System Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 China Medical System Interleukin Inhibitors for Psoriasis Product Portfolio
  66. 8.11.5 China Medical System Recent Developments
  67. 8.12 Eli Lilly
  68. 8.12.1 Eli Lilly Company Information
  69. 8.12.2 Eli Lilly Business Overview
  70. 8.12.3 Eli Lilly Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eli Lilly Interleukin Inhibitors for Psoriasis Product Portfolio
  72. 8.12.5 Eli Lilly Recent Developments
  73. 8.13 Teva
  74. 8.13.1 Teva Company Information
  75. 8.13.2 Teva Business Overview
  76. 8.13.3 Teva Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Teva Interleukin Inhibitors for Psoriasis Product Portfolio
  78. 8.13.5 Teva Recent Developments
  79. 8.14 Kyowa Kirin
  80. 8.14.1 Kyowa Kirin Company Information
  81. 8.14.2 Kyowa Kirin Business Overview
  82. 8.14.3 Kyowa Kirin Interleukin Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Kyowa Kirin Interleukin Inhibitors for Psoriasis Product Portfolio
  84. 8.14.5 Kyowa Kirin Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Interleukin Inhibitors for Psoriasis Value Chain Analysis
  2. 9.1.1 Interleukin Inhibitors for Psoriasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Interleukin Inhibitors for Psoriasis Production Mode & Process
  6. 9.2 Interleukin Inhibitors for Psoriasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Interleukin Inhibitors for Psoriasis Distributors
  9. 9.2.3 Interleukin Inhibitors for Psoriasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst